Disease Specific Guidelines and Articles
Kyle Peters, Pharm.D., BC-ADM, CDE
1. Hypertension
a. JNC VII: Link
b. DiPiro, et al. Pharmacotherapy: A Pathophysiologic approach 5th ed.
Hypertension; 157-184.
c. Atenolol twice a day meta-analysis: Link
d. Treatment of Hypertension in the Prevention and management of Ischemic Heart
Disease: Link
e. Resistant hypertension: Link
2. Cholesterol
a. ATP III: Link
b. NCEP report: Implications of recent clinical trials for the national cholesterol
education program adult treatment panel III guidelines: Link
c. 4S: Scandinavian Simvastatin Survival Study Group. Randomized trial of
cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian
Simvastatin Survival Study. Lancet 1994; 344: 1383-1389.
d. Heart Protection Study: Heart Protection Study Collaborative Group.
MRC/BHF Heart protection study of cholesterol-lowering with Simvastatin in
5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;
361: 2005-2016.
e. CARDS: Colhoun HM, Betteridge DJ, Hitman GA, et al. Primary prevention of
cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial. Lancet 2004; 364: 685-696.
f. Fasting and Nonfasting Lipid Levels: Study showing we do not have to be
fasting to have a lipid panel done. Circ. 2008:118 Link
3. Diabetes
a. ADA Clinical Practice Guidelines: Link
b. DCCT: The Diabetes Control and Complications Trial Research Group. The
effect of intensive treatment of diabetes on the development and progression of
long-term complications insulin-dependent diabetes mellitus. NEJM 1993;
329(14): 977-986. Link
c. UKPDS: UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet 1998; 352: 837-853.
d. HOPE: Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet
2000; 355: 253-259.
e. Micro-HOPE: Heart Outcomes Prevention Evaluation (HOPE) Study
Investigators. Effects of ramipril on cardiovascular and microvascular outcomes
f.
g.
h.
i.
j.
k.
l.
m.
n.
o.
p.
q.
in people with diabetes mellitus; results of the HOPE study and MICRO-HOPE
substudy. Lancet 2000; 355: 253-259.
Van de Berghe: van den Berghe G, Wouters P, Weekers F, et al. Intensive
insulin therapy in the critically ill patients. NEJM 2001; 345: 1359-1367. Link
2009 Medical Management of Hyperglycemia in Type 2 Diabetes
Consensus Statement from the ADA and EAD: Link
DKA/HHS Treatment Guidelines: Link
DKA in Kids: Link
Yale Insulin Drip Protocol: Link
28 Days/Vial of insulin: Link
Inpatient Diabetes and Glycemic Control: A Call to Action
Conference: Link
AACE Hospital Management Guidelines: Link
AACE Glycemic Control Algorithm: Link
4T Study Group: Link
eAG (Estimated Average Glucose): Link
Primary Prevention of CVD in People with DM: Link
4. CHF
a. ACC/AHA Guidelines:
Full text with 2009 focused update included: Link
2009 Focused Update: Link
Summary article not including 2009 focused update: Link
b. Yan AT, Yan RT, Liu PP. Narrative review: pharmacotherapy for chronic heart
failure: evidence from recent clinical trials. Annals of Int Med 2005; 142:132-145.
Link
5. Anticoagulation
a. 7th ACCP Conference: Link
b. Chest Guideline to Warfarin Therapy: Link
c. Chest Guideline 2008: Link
6. COPD
a. Global Initiative for Chronic Obstructive Lung Disease: Link
b. American Thoracic Society/European Respiratory Society: Link
7. Asthma
a. NAEPP EPR-3: Link
b. Asthma and Pregnancy: Link
8. Infectious Disease
a. Infectious Disease Society of America Practice Guidelines: Link
9. Renal Disease
a. KDOQI Guidelines: Link
b.
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency:
NEJ 354;2 131-140 Link
c. Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum
Creatinine: Arch Intern Med. 160:685-693 Link
d. Canadian Society of Nephrology 2008 Guidelines: Link
Review Link
1 page summary of objectives and targets: Link
10. Stroke
a. Primary Prevnetion of Stroke: Link
b. Secondary Prevention: Guidelines for Prevention of Stroke in Patients with
Ischemic Stroke or TIA: Link
c. Update to Guidelines for Prevention of Stroke: Link
11. Chronic Stable Angina:
a. 2007 ACC/AHA focused update: Link